When Funding Shaped Questions: Science as Investment
Cold Spring Harbor Laboratory, 1971. James Watson (co-discoverer of DNA structure) approaches President Richard Nixon with a proposal.
"Give us $100 million. We'll cure cancer in time for the Bicentennial (1976)."
The pitch: Cancer is molecular biology. We've cracked DNA. We can crack cancer.
Nixon agreed. December 23, 1971: Signs the National Cancer Act.
$1.5 billion immediately allocated. (About $11 billion in 2024 dollars.)
"The War on Cancer" begins.
The timeline: Cure by 1976. Five years.
The result, 50+ years later:
Cancer deaths declined (due mostly to prevention and early detection, not molecular cures).
But we didn't "cure cancer." Not even close.
Because the premise was wrong: Cancer isn't one disease. It's hundreds of diseases with different mechanisms, different genetics, different vulnerabilities. You can't solve it like cracking DNA.
But the promise of curing cancer unlocked billions in funding.
And those billions shaped what questions scientists asked, which careers flourished, which approaches dominated, and which alternative paths were abandoned.
This is the central tension in modern science:
Research requires money. Someone controls money. Whoever controls money controls questions.
Not by dictating answers—by determining what questions get asked, which methods get used, which topics get pursued.
Follow the funding, find the science.
Let's examine how science became dependent on external funding, who controls the money, how funding shapes research agendas, what gets lost when money determines questions, and whether science can ever be truly independent.
BEFORE BIG FUNDING: Gentleman Scientists and Patronage
HISTORICAL FUNDING MODELS (Pre-1940s)
PHASE 1: PERSONAL WEALTH (1600s-1800s) ┌─────────────────────────────────────────┐ │ "Gentleman scientists" │ │ ↓ │ │ Wealthy individuals pursue science as │ │ hobby/passion │ │ ↓ │ │ Examples: │ │ • Darwin (family wealth) │ │ • Cavendish (inherited fortune) │ │ • Lavoisier (tax collector income) │ │ ↓ │ │ Research questions: Personal interest │ └─────────────────────────────────────────┘
PHASE 2: ROYAL/ARISTOCRATIC PATRONAGE ┌─────────────────────────────────────────┐ │ Monarchs/nobles fund scientists │ │ ↓ │ │ Examples: │ │ • Galileo (Medici patronage) │ │ • Tycho Brahe (Danish king) │ │ • Newton (Royal Society) │ │ ↓ │ │ Research questions: Patron interest + │ │ prestige │ └─────────────────────────────────────────┘
PHASE 3: UNIVERSITY POSITIONS (1800s-1930s) ┌─────────────────────────────────────────┐ │ Universities hire faculty │ │ ↓ │ │ Salary for teaching, some research time │ │ ↓ │ │ Research equipment: Minimal │ │ ↓ │ │ Research questions: Curiosity-driven │ └─────────────────────────────────────────┘
THE LIMITATION: ┌─────────────────────────────────────────┐ │ Small-scale research only │ │ ↓ │ │ Individual scientists, limited equipment│ │ ↓ │ │ Big questions (particle physics, │ │ astronomy, molecular biology) require │ │ massive resources │ │ ↓ │ │ Can't pursue without external funding │ └─────────────────────────────────────────┘
Early science: Funded by curiosity and personal wealth.
Modern science: Too expensive for that.
THE TRANSITION: WWII and Government Science
WORLD WAR II (1939-1945)
THE CATALYST: ┌─────────────────────────────────────────┐ │ War creates urgent need for technology │ │ ↓ │ │ Radar, atomic bomb, computing, │ │ penicillin, code-breaking │ │ ↓ │ │ Governments realize: Science = military │ │ advantage │ └─────────────────────────────────────────┘
MANHATTAN PROJECT: ┌─────────────────────────────────────────┐ │ $2 billion (1940s) = ~$30 billion today │ │ ↓ │ │ 130,000 people employed │ │ ↓ │ │ Massive labs: Los Alamos, Oak Ridge │ │ ↓ │ │ Proof: Government can fund BIG science │ └─────────────────────────────────────────┘
POST-WAR LOGIC: ┌─────────────────────────────────────────┐ │ Vannevar Bush (Science Advisor): │ │ "Basic research drives technology" │ │ ↓ │ │ Argument to Congress: Fund basic │ │ science → technological superiority │ │ ↓ │ │ 1950: National Science Foundation (NSF) │ │ created │ │ ↓ │ │ Government becomes primary funder │ └─────────────────────────────────────────┘
COLD WAR ACCELERATION: ┌─────────────────────────────────────────┐ │ Sputnik (1957): USSR launches satellite │ │ ↓ │ │ U.S. panic: "We're behind!" │ │ ↓ │ │ Massive funding increase: │ │ • NASA created (1958) │ │ • DARPA created (1958) │ │ • NIH expanded enormously │ │ ↓ │ │ Science funding = national security │ └─────────────────────────────────────────┘
The shift: From curiosity-driven to mission-driven funding.
Science became investment in national power.
THE FUNDERS: Who Controls the Money?
MAJOR FUNDING SOURCES (U.S. Model, 2020s)
FEDERAL GOVERNMENT: ┌─────────────────────────────────────────┐ │ National Institutes of Health (NIH): │ │ • Budget: ~$47 billion/year (2024) │ │ • Focus: Biomedical research, health │ │ ↓ │ │ National Science Foundation (NSF): │ │ • Budget: ~$10 billion/year │ │ • Focus: Basic science across fields │ │ ↓ │ │ Department of Defense (DOD): │ │ • Budget: ~$15 billion/year for R&D │ │ • Focus: Military applications │ │ ↓ │ │ Department of Energy (DOE): │ │ • Budget: ~$8 billion/year for science │ │ • Focus: Energy, physics, computing │ │ ↓ │ │ NASA: │ │ • Budget: ~$7 billion/year for science │ │ • Focus: Space, Earth science │ └─────────────────────────────────────────┘
PRIVATE FOUNDATIONS: ┌─────────────────────────────────────────┐ │ Howard Hughes Medical Institute: ~$1B/yr│ │ Gates Foundation: ~$500M/yr for science │ │ Wellcome Trust: ~$1.5B/yr │ │ ↓ │ │ Focus: Specific priorities (global │ │ health, neglected diseases) │ └─────────────────────────────────────────┘
INDUSTRY: ┌─────────────────────────────────────────┐ │ Pharmaceutical companies │ │ Tech companies (Google, Microsoft) │ │ Oil/energy companies │ │ ↓ │ │ Focus: Commercially relevant research │ └─────────────────────────────────────────┘
UNIVERSITIES: ┌─────────────────────────────────────────┐ │ Small internal grants │ │ ↓ │ │ But most university research: Funded by │ │ external sources (government, industry) │ └─────────────────────────────────────────┘
Government dominates.
And government has priorities.
HOW FUNDING SHAPES SCIENCE: The Mechanisms
FUNDING INFLUENCE PATHWAYS
MECHANISM 1: TOPIC SELECTION ┌─────────────────────────────────────────┐ │ Funder announces priority areas │ │ ↓ │ │ Example: "NIH Priority: Alzheimer's" │ │ ↓ │ │ Scientists write proposals in that area │ │ ↓ │ │ Other topics: Unfunded │ │ ↓ │ │ Result: Research flows to funded topics │ └─────────────────────────────────────────┘
MECHANISM 2: METHODOLOGICAL BIAS ┌─────────────────────────────────────────┐ │ Funders prefer certain approaches: │ │ • RCTs (randomized controlled trials) │ │ • Quantitative over qualitative │ │ • Reductionist over holistic │ │ ↓ │ │ Alternative methods: Harder to fund │ │ ↓ │ │ Result: Methods favored by funders │ │ dominate │ └─────────────────────────────────────────┘
MECHANISM 3: TIMESCALE CONSTRAINTS ┌─────────────────────────────────────────┐ │ Grants typically: 3-5 years │ │ ↓ │ │ Long-term projects (10+ years): Risky │ │ ↓ │ │ Scientists propose projects completable │ │ in grant period │ │ ↓ │ │ Result: Short-term focus, incremental │ │ progress favored │ └─────────────────────────────────────────┘
MECHANISM 4: PRELIMINARY DATA REQUIREMENT ┌─────────────────────────────────────────┐ │ Grant applications require: "Preliminary│ │ data proving feasibility" │ │ ↓ │ │ But: Need funding to GET preliminary │ │ data │ │ ↓ │ │ Catch-22: Need results to get funding, │ │ need funding to get results │ │ ↓ │ │ Result: Truly novel projects difficult │ │ to start │ └─────────────────────────────────────────┘
MECHANISM 5: SUCCESS RATE PRESSURE ┌─────────────────────────────────────────┐ │ NIH success rate: ~20% (2020s) │ │ ↓ │ │ Scientists write safe, incremental │ │ proposals (higher chance of funding) │ │ ↓ │ │ Risky, transformative ideas: Lower │ │ success probability │ │ ↓ │ │ Result: Conservatism in proposal writing│ └─────────────────────────────────────────┘
Funding doesn't dictate conclusions.
But it absolutely shapes which questions get asked.
CASE STUDY 1: The War on Cancer—Mission-Driven Science
NATIONAL CANCER ACT (1971-Present)
THE PROMISE: ┌─────────────────────────────────────────┐ │ Nixon: "Cure cancer in 5 years" │ │ ↓ │ │ Massive funding: Initially $1.5B, now │ │ $7+ billion/year (NCI budget) │ │ ↓ │ │ Logic: Cancer = molecular problem. │ │ Find genetic causes, develop targeted │ │ therapies │ └─────────────────────────────────────────┘
WHAT FUNDING SHAPED: ┌─────────────────────────────────────────┐ │ 1. MOLECULAR FOCUS │ │ Research on genes, mutations, │ │ molecular pathways │ │ ↓ │ │ 2. BIOMEDICAL MODEL │ │ Less funding for: │ │ • Environmental causes │ │ • Prevention │ │ • Social determinants │ │ ↓ │ │ 3. TREATMENT OVER PREVENTION │ │ Drug development prioritized over │ │ reducing carcinogen exposure │ └─────────────────────────────────────────┘
RESULTS (50+ years later): ┌─────────────────────────────────────────┐ │ SUCCESSES: │ │ • Childhood leukemia: 90% cure rate │ │ • Hodgkin's lymphoma: 85% cure rate │ │ • Testicular cancer: 95% cure rate │ │ • Targeted therapies (Gleevec, etc.) │ │ ↓ │ │ LIMITATIONS: │ │ • Most common cancers (lung, colon, │ │ breast, pancreatic): Still deadly │ │ • Overall cancer mortality: Declined │ │ 25% (mostly prevention/early │ │ detection, not cures) │ │ • "Cure cancer" goal: Not achieved │ └─────────────────────────────────────────┘
WHAT WASN'T FUNDED: ┌─────────────────────────────────────────┐ │ • Large-scale carcinogen regulation │ │ • Reducing industrial exposures │ │ • Obesity/lifestyle interventions │ │ • Environmental cleanup │ │ ↓ │ │ Why? These are prevention, not cures │ │ ↓ │ │ Political resistance from industry │ └─────────────────────────────────────────┘
Funding drove research toward molecular cures.
Prevention, environmental causes—less funding, less attention.
Not because scientists didn't care—because money flowed elsewhere.
CASE STUDY 2: Pharmaceutical Industry Funding—Conflicts of Interest
INDUSTRY-FUNDED RESEARCH
THE SCALE: ┌─────────────────────────────────────────┐ │ Pharmaceutical companies fund ~30-40% │ │ of biomedical research (varies by │ │ country) │ │ ↓ │ │ Clinical trials: Often industry-funded │ │ ↓ │ │ Medical schools: Industry gifts, │ │ partnerships │ └─────────────────────────────────────────┘
THE BIAS: ┌─────────────────────────────────────────┐ │ Industry-funded studies: │ │ ↓ │ │ • 3-4x more likely to find positive │ │ results for sponsor's drug │ │ ↓ │ │ • Less likely to publish negative │ │ findings │ │ ↓ │ │ • More likely to compare to placebo │ │ (not competitor drug) │ │ ↓ │ │ • More likely to use favorable outcome │ │ measures │ └─────────────────────────────────────────┘
MECHANISMS OF BIAS: ┌─────────────────────────────────────────┐ │ 1. PUBLICATION BIAS: │ │ Negative results filed away, not │ │ published │ │ ↓ │ │ 2. DESIGN CHOICES: │ │ Study designed to favor sponsor's │ │ drug (dose, comparator, endpoints) │ │ ↓ │ │ 3. SELECTIVE REPORTING: │ │ Report favorable outcomes, bury │ │ unfavorable │ │ ↓ │ │ 4. GHOST WRITING: │ │ Company writes paper, academic signs │ │ as author │ └─────────────────────────────────────────┘
EXAMPLES: ┌─────────────────────────────────────────┐ │ VIOXX (Merck): │ │ • Painkiller, $2.5B/year sales │ │ • Increased heart attack risk │ │ • Company-funded studies downplayed risk│ │ • Withdrawn 2004, after ~60,000 deaths │ │ ↓ │ │ PAXIL (GSK): │ │ • Antidepressant │ │ • Study showed ineffective in teens │ │ • Company published misleading positive │ │ summary │ │ • Prescribed to teens anyway │ │ ↓ │ │ OXYCONTIN (Purdue): │ │ • Company funded studies claiming low │ │ addiction risk │ │ • Opioid epidemic resulted │ └─────────────────────────────────────────┘
Industry funding doesn't always corrupt.
But it systematically biases toward sponsor interests.
And that shapes medical knowledge, clinical practice, patient outcomes.
CASE STUDY 3: Military Funding—DARPA and Directed Research
DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)
THE MODEL: ┌─────────────────────────────────────────┐ │ Created 1958 (post-Sputnik) │ │ ↓ │ │ Budget: ~$4 billion/year │ │ ↓ │ │ Mission: High-risk, high-reward research│ │ for military advantage │ └─────────────────────────────────────────┘
DARPA'S SUCCESSES: ┌─────────────────────────────────────────┐ │ • ARPANET → Internet │ │ • GPS (Global Positioning System) │ │ • Stealth aircraft technology │ │ • Computer mouse, graphical interfaces │ │ • Speech recognition │ │ • mRNA vaccine technology (ADEPT │ │ program, pre-COVID) │ └─────────────────────────────────────────┘
THE APPROACH: ┌─────────────────────────────────────────┐ │ "Program managers" with specific goals │ │ ↓ │ │ Fund multiple approaches simultaneously │ │ ↓ │ │ Accept high failure rate (most projects │ │ fail, but a few succeed dramatically) │ │ ↓ │ │ Application-driven (not curiosity) │ └─────────────────────────────────────────┘
WHAT THIS SHAPES: ┌─────────────────────────────────────────┐ │ Research focuses on: │ │ • Dual-use technologies (military + │ │ civilian applications) │ │ • Engineering over pure science │ │ • Short-to-medium timescales (3-5 yrs) │ │ ↓ │ │ Less funding for: │ │ • Pure curiosity-driven research │ │ • Long-term basic science (no immediate │ │ application) │ │ • Research with no military relevance │ └─────────────────────────────────────────┘
THE TRADE-OFF: ┌─────────────────────────────────────────┐ │ PRO: High-risk research funded (most │ │ funders avoid risk) │ │ ↓ │ │ CON: Applications must be defensible as │ │ military-relevant │ │ ↓ │ │ Result: Some basic science gets funded │ │ (if military justification exists) │ └─────────────────────────────────────────┘
DARPA proves directed funding can work.
But direction = priorities.
And priorities determine what science happens.
WHAT GETS LOST: The Unfunded Questions
SYSTEMATICALLY UNDERFUNDED RESEARCH
UNFASHIONABLE TOPICS: ┌─────────────────────────────────────────┐ │ Research on diseases affecting poor │ │ countries │ │ ↓ │ │ Example: Neglected tropical diseases │ │ (affects 1+ billion people) │ │ ↓ │ │ Funding: Tiny fraction of biomedical │ │ research │ │ ↓ │ │ Why? Patients can't pay for treatments │ │ → No commercial incentive │ └─────────────────────────────────────────┘
NEGATIVE RESULTS: ┌─────────────────────────────────────────┐ │ "We tested X. It didn't work." │ │ ↓ │ │ Scientifically valuable (avoids future │ │ dead ends) │ │ ↓ │ │ Funding: Almost impossible to get grant │ │ to publish null results │ │ ↓ │ │ Result: Literature biased toward │ │ positive findings │ └─────────────────────────────────────────┘
REPLICATION STUDIES: ┌─────────────────────────────────────────┐ │ "We repeated study X to verify" │ │ ↓ │ │ Essential for science (see Core #41) │ │ ↓ │ │ Funding: Extremely rare │ │ ↓ │ │ Why? Not novel, not exciting │ └─────────────────────────────────────────┘
LONG-TERM, SLOW RESEARCH: ┌─────────────────────────────────────────┐ │ Ecological studies (decades of data) │ │ Longitudinal health studies │ │ Climate monitoring │ │ ↓ │ │ Funding: Difficult (requires sustained │ │ commitment beyond grant cycles) │ │ ↓ │ │ Result: Underrepresented in literature │ └─────────────────────────────────────────┘
POLITICALLY INCONVENIENT RESEARCH: ┌─────────────────────────────────────────┐ │ Gun violence research (blocked by │ │ Congress, 1996-2019) │ │ ↓ │ │ Climate change research (historically │ │ politically fraught) │ │ ↓ │ │ Drug policy research (marijuana, etc.) │ │ ↓ │ │ Funding: Blocked or restricted │ └─────────────────────────────────────────┘
INTERDISCIPLINARY WORK: ┌─────────────────────────────────────────┐ │ Falls between traditional departments │ │ ↓ │ │ Grant review panels: Disciplinary │ │ ↓ │ │ Interdisciplinary proposals: Don't fit │ │ review criteria │ │ ↓ │ │ Funding: Lower success rate │ └─────────────────────────────────────────┘
The questions that don't get asked are invisible.
We only see the research that got funded.
THE FEEDBACK LOOP: How Funding Perpetuates Itself
THE MATTHEW EFFECT IN SCIENCE FUNDING
CYCLE 1: INITIAL SUCCESS ┌─────────────────────────────────────────┐ │ Researcher gets grant │ │ ↓ │ │ Publishes papers │ │ ↓ │ │ Papers = preliminary data for next grant│ │ ↓ │ │ Next grant easier to get │ └─────────────────────────────────────────┘
CYCLE 2: ACCUMULATION ┌─────────────────────────────────────────┐ │ Multiple grants → more staff, equipment │ │ ↓ │ │ More staff → more papers │ │ ↓ │ │ More papers → more grants │ │ ↓ │ │ Rich get richer │ └─────────────────────────────────────────┘
CYCLE 3: EXCLUSION ┌─────────────────────────────────────────┐ │ Unfunded researcher: │ │ • No preliminary data │ │ • No staff to generate data │ │ • Can't compete with well-funded labs │ │ ↓ │ │ Can't get funded │ │ ↓ │ │ Leaves science or works in funded areas │ └─────────────────────────────────────────┘
THE RESULT: ┌─────────────────────────────────────────┐ │ Funding concentrates in: │ │ • Elite institutions │ │ • Established researchers │ │ • Trendy topics │ │ ↓ │ │ New ideas, new researchers, unfashionable│ │ topics: Systematically disadvantaged │ └─────────────────────────────────────────┘
Funding creates self-reinforcing hierarchies.
Success breeds success. Failure is permanent.
CAN SCIENCE BE INDEPENDENT?
THE INDEPENDENCE QUESTION
THE IDEAL: ┌─────────────────────────────────────────┐ │ "Pure science" driven by curiosity │ │ ↓ │ │ Scientists ask important questions │ │ ↓ │ │ Regardless of funding availability │ └─────────────────────────────────────────┘
THE REALITY: ┌─────────────────────────────────────────┐ │ Modern science requires: │ │ • Labs (expensive) │ │ • Equipment (very expensive) │ │ • Staff (salaries) │ │ • Computing (expensive) │ │ • Materials (ongoing costs) │ │ ↓ │ │ No individual can self-fund │ │ ↓ │ │ Must get external funding │ └─────────────────────────────────────────┘
THE OPTIONS: ┌─────────────────────────────────────────┐ │ 1. GOVERNMENT FUNDING: │ │ Pro: Largest source, relatively │ │ independent │ │ Con: Political priorities, budget │ │ fluctuations │ │ ↓ │ │ 2. INDUSTRY FUNDING: │ │ Pro: Large budgets, efficient │ │ Con: Commercial bias, IP restrictions│ │ ↓ │ │ 3. FOUNDATION FUNDING: │ │ Pro: Can support unfashionable topics│ │ Con: Limited scale, specific agendas │ │ ↓ │ │ 4. CROWDFUNDING: │ │ Pro: Democratic, bypass gatekeepers │ │ Con: Tiny amounts, popularity bias │ └─────────────────────────────────────────┘
THE CONCLUSION: ┌─────────────────────────────────────────┐ │ Complete independence: Impossible │ │ ↓ │ │ Best option: Diverse funding sources │ │ (no single funder dominates) │ │ ↓ │ │ But: This requires coordination, │ │ sustained support │ └─────────────────────────────────────────┘
Science can't be independent.
But it can be diversely funded—which limits any single funder's control.
CONCLUSION: Science as Investment Portfolio
Science in the 21st century is investment.
Governments invest for national security, public health, economic competitiveness.
Industries invest for profitable products.
Foundations invest for specific missions (global health, climate, education).
This isn't corrupt. It's inevitable.
Modern science is too expensive for wealthy hobbyists. It requires institutions, infrastructure, sustained funding.
But investment means priorities.
And priorities shape the questions that get asked.
The War on Cancer shaped a generation of researchers toward molecular biology, treatment over prevention, biomedical interventions over environmental regulation.
Pharmaceutical funding biases toward commercially viable drugs, against treatments that can't be patented (lifestyle, generics, repurposed drugs).
Military funding directs research toward dual-use technologies, short timescales, engineering applications.
The invisible losses:
- Questions that don't align with funder priorities
- Long-term research requiring sustained commitment
- Politically inconvenient findings
- Negative results and replication studies
- Research benefiting populations who can't pay
The paradox:
Science claims objectivity—following evidence wherever it leads.
But funding determines where scientists look.
Can't follow evidence you're not funded to collect.
The hardening of science required systematic investigation.
But systematic investigation requires resources.
And whoever controls resources shapes what gets investigated.
Science isn't neutral.
It's shaped by the interests of those who pay for it.
Not through fraud or coercion—but through the simple mechanism of deciding which questions get asked.
And in science, the questions you don't ask are invisible.
[Cross-references: For how journals amplify funded research, see "When Journals Became Gatekeepers: Controlling Scientific Truth" (Core #42). For reproducibility crisis partly caused by funding pressure, see "The Reproducibility Crisis: When Science Couldn't Replicate Itself" (Core #41). For pharmaceutical conflicts, see Biology Companion #110-111. For military funding of physics, see Physics Companion #75-76. For professionalization of science, see "When Science Became a Job: Professionalization" (Core #31). For Cold War science funding, see "When Research Required Nations: Big Science" (Core #33). For open science and alternative funding models, see "What Comes After Falsification? New Epistemologies" (Core #48).]